<DOC>
	<DOCNO>NCT01955772</DOCNO>
	<brief_summary>Myeloablative allogeneic hematopoetic stem cell transplantation ( AHSCT ) prone frequent secondary malnutrition metabolic digestive trouble due condition regimen , treatment ( antibiotic , immunosuppressive therapyâ€¦ ) graft complication ( graft versus host disease ) . In absence appropriate nutritional support , myeloablative conditioning lead rapid serious denutrition . But , know negative independent prognostic factor overall survival patient present malignant hemopathy treat high-dose chemotherapy AHSCT . Furthermore , increase hospitalisation delay decrease quality life . In AHSCT myeloablative conditioning , introduction nutritional support recommend . However , type nutritional support remain clearly define . Parenteral nutrition user favour infection secondary effect potentially decrease intravenous glutamine . Few previous study low number patient , mainly retrospective combine allo-and auto HSCT show feasibility , acceptable tolerance low cost enteral nutrition ( EN ) . A recent prospective no-randomized study 45 adult patient undergone AHSCT myeloablative conditioning find significant decrease day-100 mortality ( 5 % vs 30 % ) , infection mortality , median duration parenteral nutrition ( PN ) prevalence GvH ( Graft versus Host Disease ) grade III-IV EN ( enteral nutrition ) group . These result confirm randomized study . As EN 4 5 cheaply PN , besides mortality/morbidity stake patient , study could potential economic interest .</brief_summary>
	<brief_title>Randomized , Prospective , Multicenter Study Compare Enteral Nutrition Parenteral Nutrition Feeding Support Patients Presenting Malignant Hemopathy Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation .</brief_title>
	<detailed_description>EN ( enteral nutrition ) PN ( parenteral nutrition ) artificial nutrition launch D1-D2 transplantation ( D0 day transplantation ) , without take account oral intake . This help particular launch EN stage significant digestive problem related condition mucositis appearance . EN group : According HAS SFNEP ( Societe francophone nutrition clinique ) recommendation good practice rule , polyurethane silicone NGT ( Naso gastric tube ) , 8 10 French unit , insert position control radiography EN beginning . Polyurethane silicone well tolerate nasal oesophagus mucosa long life duration allow keep tube 2 3 month . PN group : PN administrate central venous catheter , usually insert allo-HSCT patient allow administration chemotherapy different parenteral treatment .</detailed_description>
	<criteria>Age 18 65 year Men woman Patients undergo myeloablative alloSCT AlloSCT genoidentical phenoidentical 10/10 Patients affiliated social security organisation Patients sign informed consent Status tumour progression moment alloSCT Artificial nutrition begin inclusion Inability understand protocol ( linguistic barrier , cognitive difficulty ) Contraindication associate pathology allow carry EN PN accord protocol Medical history progressive psychiatric illness Medical history another progressive cancer occurrence 5 previous year Presence simultaneous serious uncontrolled disease severe cardiac , renal , hepatic respiratory failure severe sepsis Previous alloSCT Participation another clinical trial study allograft procedure , apply modality available routine practice ( include innovative immunosuppression graft conditioning regimen consider myeloablative )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Haematopoietic stem cell transplantation</keyword>
	<keyword>Malignant hemopathy</keyword>
	<keyword>Artificial nutrition</keyword>
</DOC>